Science // Petrie-Flom Center
Lykos Therapeutics’s failure to win approval may trigger a strategic shift in psychedelic medicine. By Kai Kupferschmidt, featuring I. Glenn Cohen.
FDA rejected MDMA-assisted PTSD therapy. Other psychedelics firms intend to avoid that fate